{"id":"NCT00645411","sponsor":"Novartis","briefTitle":"Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents","officialTitle":"A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Children and Adolescents","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-10","primaryCompletion":"2008-02","completion":"2008-07","firstPosted":"2008-03-27","resultsPosted":"2013-01-16","lastUpdate":"2015-11-23"},"enrollment":3604,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Cell culture-derived influenza subunit vaccine (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Egg derived influenza subunit vaccine (eTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Cell culture-derived influenza subunit vaccine (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Egg derived influenza subunit vaccine (eTIV)","otherNames":[]}],"arms":[{"label":"Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV","type":"EXPERIMENTAL"},{"label":"Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 3 (3-8 Yrs) cTIV","type":"EXPERIMENTAL"},{"label":"Cohort 3 (3-8 Yrs) eTIV","type":"ACTIVE_COMPARATOR"}],"summary":"The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years. A step-down approach is utilized in which reactogenicity and safety will be assessed in children and adolescents 9 to 17 years of age (Cohort 1) prior to enrolling additional children and adolescents 9 to 17 years of age (Cohort 2) and children 3 to 8 years of age (Cohort 3).","primaryOutcome":{"measure":"Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children","timeFrame":"Day 50 post vaccination","effectByArm":[{"arm":"Cohort 3 cTIV (3-8 Years)","deltaMin":407,"sd":null},{"arm":"Cohort 3 eTIV (3-8 Years)","deltaMin":477,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States","Croatia","Finland","Hungary","Italy","Lithuania","Romania"]},"refs":{"pmids":["22301476"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":652},"commonTop":["Injection site pain","Injection site erythema","Headache","Fatigue","Myalgia"]}}